Regulatory T cells (Tregs) play an indispensable role in maintaining immunological unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host. Tregs are produced in the thymus as a functionally mature subpopulation of T cells and can also be induced from naive T cells in the periphery. Recent research reveals the cellular and molecular basis of Treg development and function and implicates dysregulation of Tregs in immunological disease.
Introduction
The mammalian immune system protects the host from a broad range of pathogenic microorganisms while avoiding misguided or excessive immune reactions that would be deleterious to the host. Both protective and harmful immune responses are principally mediated by T and B cells, which possess enormous diversity in antigen recognition, high antigen specificity, potent effector activity, and long-lasting immunologic memory. Because of this potency, serious damage to the host may ensue if aberrant immune responses, such as autoimmunity or allergy, are triggered. A major challenge in immunology and medicine is to determine how unresponsiveness of the adaptive immune system to self-antigens (that is, immunological self-tolerance) is established and maintained, and how the quality and magnitude of adaptive immune responses to non-self-antigens are controlled so as to avoid damage to the host. Understanding the mechanisms of immunological self-tolerance will also provide insights into how weak immune responses, such as those against tumor antigens in cancer patients or against microbial antigens in chronic infection, can be augmented, or conversely, how strong immune responses such as graft rejection can be restrained.
There are two types of mechanisms, "recessive" and "dominant," for achieving self-tolerance and immune homeostasis. In the recessive mechanisms of self-tolerance, the fate of antigenexposed self-reactive lymphocytes is determined in a cell-intrinsic manner. For example, some lymphocytes are programmed to die by apoptosis when exposed to self-antigen at an immature stage of their development in the central generative organs (the thymus for T cells and the bone marrow for B cells). Other lymphocytes may replace self-reactive T cell or B cell receptors (TCRs and BCRs, respectively) with nonreactive ones, a process called receptor editing. Those that have escaped clonal deletion and receptor editing may further mature but can be rendered anergic (functionally inactivated) upon exposure to selfantigen. In addition, their activation thresholds may be raised by the expression of inhibitory receptors or negative signaling molecules or they may not survive long because of activationinduced cell death. The cell-intrinsic control of cell fate or activation threshold also contributes to the inhibition of excessive immune responses to non-self-antigens.
In the dominant or cell-extrinsic mechanism, certain T cells actively keep in check the activation and expansion of aberrant or overreactive lymphocytes, in particular other types of T cells. Until recently, the physiological significance, and even the existence of T cell-mediated immune suppression, has been highly contentious. Yet there is now firm evidence that the normal immune system produces a population of T cells, called regulatory T cells (Tregs) , that are specialized for immune suppression. Disruption in the development or function of Tregs is a primary cause of autoimmune and inflammatory diseases in humans and animals. Moreover, it is now emerging that every adaptive immune response involves recruitment and activation of not only effector T and B cells but also Tregs, and that the balance between the two populations is critical for the proper control of the quality and magnitude of adaptive immune responses and for establishing or breaching tolerance to self-and non-self-antigens.
In this Review, we discuss the roles of Tregs in self-tolerance and immune homeostasis, the cellular and molecular basis of their development and function, and how they might be exploited at the cellular and molecular levels to control a wide spectrum of physiological and pathological immune responses.
Thymus-Derived Tregs
It has been known for nearly 40 years that simple manipulation of the thymus and T cells, but not self-antigen, can produce autoimmune disease in normal animals (reviewed in Sakaguchi, 2000) . Neonatal thymectomy at a critical period (around day 3 after birth) of selected strains of normal mice results in autoimmune damage of various organs (such as the thyroid, stomach, ovaries, and testes) and the appearance of tissue-specific autoantibodies in the circulation. Adult thymectomy of selected strains of normal rats followed by several rounds of sublethal X-irradiation produces autoimmune thyroiditis and type I diabetes. Importantly, inoculation of normal T cells, in particular CD4 + T cells or CD4 + CD8 − thymocytes, from untreated syngeneic animals inhibits the development of autoimmunity (Sakaguchi et al., 1982; Fowell and Mason, 1993) . These results indicated that normal animals harbor not only potentially pathogenic selfreactive T cells but also T cells that suppress autoimmunity, with the latter dominantly controlling the former. A critical experiment to prove this interpretation was to identify autoimmunesuppressive T cells using a definitive phenotypic marker and to determine whether removal of the population from normal adult animals disrupts self-tolerance and leads to autoimmune disease. Indeed, when CD4 + T cell suspensions from the spleens of normal mice or rats were depleted of cells bearing a particular marker profile (CD5 high or CD45RC low ) ex vivo, and the remaining CD4 + T cells were transferred to syngeneic T cell-deficient athymic nude mice or rats, the recipients spontaneously developed autoimmune disease in multiple organs within a few months (Sakaguchi et al., 1985; Powrie and Mason, 1990 ) ( Figure 1A) . Reconstitution of the depleted CD4 + T cell subpopulation inhibited autoimmunity. Subsequent efforts to search for a more specific marker with which to delineate the putative autoimmune-preventive CD4 + T cells revealed the CD25 molecule (the IL-2 receptor α chain) as a candidate (Sakaguchi et al., 1995) . Transfer of T cell suspensions depleted of CD25 + T cells indeed produces autoimmune disease in athymic nude mice, whereas cotransfer of a small number of CD25 + CD4 + T cells clearly inhibits the development of autoimmunity.
Notably, depletion of naturally arising Tregs not only elicits autoimmunity but also augments immune responses to non-self-antigens. Treg depletion produces inflammatory bowel disease, which likely results from excessive immune responses to commensal bacteria in the intestine (Singh et al., 2001) . Removal or reduction of CD25 + CD4 + Tregs also provokes effective tumor immunity in otherwise nonresponding animals and augments microbial immunity in chronic infection, leading to eradication of tumors or microbes, respectively (reviewed in Wang and Wang, 2007; Belkaid and Rouse, 2005) . Conversely, CD25 + CD4 + T cells enriched from normal mice suppress allergy, establish tolerance to organ grafts, prevent graft-versus-host disease after bone marrow transplantation, and promote feto-maternal tolerance (reviewed in Sakaguchi, 2005) ( Figure 1A ). CD25 + CD4 + Tregs are also present in the periphery of humans (reviewed in Baecher-Allan et al., 2004) . T cells that are reactive with a particular self-antigen targeted in autoimmune disease (such as glutamic acid decarboxylase in type I diabetes) or a tumor-associated antigen can be easily expanded in vitro from peripheral blood of normal healthy individuals when T cells are stimulated with self or tumor antigen after depletion of CD25 + CD4 + Tregs (Danke et al., 2004) .
With these findings, it is possible to formulate several key notions concerning dominant self-tolerance and immune regulation. First, the normal immune system generates CD25 + CD4 + Tregs that are engaged in suppressing immune responses toward self, quasi-self (such as autologous tumor cells), and non-self (such as microbes and allografts). Second, the normal thymus produces potentially pathogenic selfreactive T cells as well as functionally mature Tregs; mature Tregs persist in the periphery and exert dominant control over the self-reactive T cells. Third, Treg deficiency in the periphery is sufficient to evoke chronic T cell-mediated autoimmunity and immunopathology.
Foxp3 Controls Treg Development and Function
Naturally occurring Tregs specifically express the transcription factor Foxp3 (forkhead box P3), a member of the forkhead/winged-helix family of transcription factors. Foxp3 is a master regulator of Treg development and function. The Foxp3 gene was first identified as the defective gene in the mouse strain Scurfy. Surfy is an X-linked recessive mutant that is lethal in hemizygous males within a month after birth, exhibiting hyperactivation of CD4 + T cells and overproduction of proinflammatory cytokines (Brunkow et al., 2001) . Mutations of the human gene FOXP3 are the cause of the genetic disease IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), which is the human counterpart of Scurfy (reviewed in Ochs et al., 2005;  Figure 1B ).
Immunological and clinical similarities between IPEX in humans and autoimmunity/inflammation produced in rodents by Treg depletion prompted researchers to determine the possible role of Foxp3 in Treg development and function (Hori et al., 2003; Khattri et al., 2003; Fontenot et al., 2003 (Hori et al., 2003) . Foxp3 transduction in naive T cells also upregulates the expression of CD25 and other Tregassociated cell-surface molecules, such as cytotoxic T cellassociated antigen-4 (CTLA-4) and glucocorticoid-induced TNF receptor family-related gene/protein (GITR), whereas it represses the production of IL-2, IFN-γ, and IL-4. Both Foxp3-deficient mice and Scurfy mice, whose Foxp3 protein lacks the forkhead domain, harbor few CD25 + CD4 + Tregs, and inoculation of CD25 + CD4 + T cells from normal mice prevents severe systemic inflammation in Scurfy mice (Fontenot et al., 2003) . In bone marrow chimera with a mixture of cells from wild-type and Foxp3-deficient mice, Foxp3-deficient bone marrow cells failed to give rise to CD25 + CD4 + Tregs, whereas Foxp3-intact bone marrow cells generated Tregs that suppressed disease development. Conversely, in transgenic mice that overexpress Foxp3, the number of CD25 + CD4 + T cells is enhanced; CD25 − CD4 + T cells and CD8 + T cells expressed high levels of Foxp3 and exerted suppression in vitro (Khattri et al., 2003) . Recent analyses reveal that Foxp3-expressing T cells appear shortly after birth and show that the development of autoimmune/inflammatory disease follows their depletion (Kim et al., 2007; Lahl et al., 2007) .
Thus, the transcription factor Foxp3 is critical for α/β TCRpositive T cells to differentiate to Tregs in the thymus (Figure 1C) . High-level expression of Foxp3 is sufficient to confer suppressive activity to normal non-Treg cells. Further, genetic disruption of Foxp3 in humans and mice provides unequivocal evidence that dominant self-tolerance is operating in both species ( Figure 1B) . Foxp3 is currently the most reliable molecular marker for natural Tregs and provides clues with which to decipher the molecular and genetic basis of Treg development and function.
Interleukin 2 Maintains Foxp3
+ Tregs Interleukin 2 (IL-2) is another molecule critical for the function of Tregs. The Treg marker CD25 is a component of the highaffinity IL-2 receptor (IL-2R) and is functionally essential for Treg development. IL-2 has long been thought to be a major cytokine for T cell proliferation and differentiation based on its effects on T cell growth in vitro. It has therefore been puzzling that mice lacking IL-2 do not exhibit serious defects in T cell differentiation and function. Instead, these mice spontaneously develop T cell-mediated fatal lymphoproliferative/ inflammatory disease with autoimmune components (such as hemolytic anemia and lymphocytic infiltration into multiple organs) and hyperreactivity to commensal microbes (reviewed in Malek and Bayer, 2004) . Mice deficient in CD25 or CD122 (another component of the IL-2R) also succumb to a similar set of ailments, generally called IL-2 deficiency syndrome. In humans, CD25 deficiency, which accompanies severe autoimmunity and allergy, is indistinguishable from IPEX (Caudy et al., 2007) . Evidence suggests that the syndrome is due to deficiency or dysfunction of Foxp3 + Tregs. First, the number of Foxp3 + Tregs is reduced in mice lacking either CD25 or IL-2 (Antony et al., 2006) , and autoimmunity in CD25-deficient mice can be prevented by inoculating them with wild-type CD25 + CD4 + T cells (reviewed in Malek and Bayer, 2004) . Second, T cell-specific deficiency of STAT5a and b, which mediate signaling from the IL-2R β chain to the nucleus, abrogates the development of Foxp3 + Tregs, producing autoimmune/inflammatory disease (Burchill et al., 2007; Yao et al., 2007) . Third, administration of a high dose of neutralizing anti-IL-2 monoclonal antibody to normal neonatal mice substantially reduces the number of Foxp3 + CD25 + CD4 + T cells for a limited period and elicits autoimmune diseases similar to those produced by Treg depletion (Setoguchi et al., 2005) . In addition, IL-2 is required for sustained expression of Foxp3 and CD25 in natural Tregs and enhances their suppressive function, at least in vitro (Fontenot et al., 2005; Shevach et al., 2006) . Although other γ c cytokines also contribute to Treg development and maintenance, they are unable to fully replace the roles of IL-2 or prevent IL-2 deficiency syndrome. For example, in contrast with mild reduction of Foxp3 + cells in mice lacking either IL-2 or CD25, deficiency of CD122 (shared by IL-2R and IL-15R) or CD132 (shared by IL-2R, IL-4R, IL-7R, IL-9R, IL-21R, and IL-15R),or double deficiency of IL-2 and IL-15 lead to a profound reduction in the number of Tregs (Fontenot et al., 2005; Burchill et al., 2007 + natural Tregs, expands them at high doses, and facilitates TGF-β-dependent differentiation of naive T cells to Foxp3 + Tregs, but inhibits TGF-β/IL-6-dependent differentiation of naive T cells to inflammatory Th17 cells . Thus, assuming that the main source of IL-2 is activated T cells, there is a negative feedback control of immune responses via IL-2; that is, IL-2 produced by activated nonregulatory T cells contributes to the maintenance, expansion, and activation of natural Tregs, which in turn limits the expansion of nonregulatory T cells (Figure 2) . Disruption of this IL-2-mediated feedback loop at any step promotes the development of autoimmune/inflammatory disease. Further, manipulation of this feedback loop is instrumental in tuning the intensity of Treg-mediated suppression, hence the strength of a variety of immune responses.
Control of Treg Function by Foxp3
How does Foxp3 orchestrate the cellular and molecular programs involved in Treg function? It has been shown that Foxp3, which appears to operate as a homo-oligomer, interacts with the transcription factors NFAT (nuclear factor of activated T cells), AML1 (acute myeloid leukemia-1)/Runx1 (runt-related transcription factor 1), the histone acetyl transferase (HAT)/histone deacetyl transferase (HDAC) complex, and possibly NF-κB ( Figure 3A) .
The activity of NFAT is controlled by calcium and the calcium-dependent protein phosphatase calcineurin. Upon activation, NFAT forms a complex with AP-1 and NF-kB and promotes the expression of Il2, Il4, Ctla4, and other genes in conventional T cells, thus contributing to the activation of T cells and their differentiation to effector T cells (reviewed in Rao et al., 1997) . A recent study has shown that the interaction between Foxp3 and NFAT is dependent upon their cooperative binding to DNA (Wu et al., 2006) . Amino acid substitutions in the forkhead domain of Foxp3 that disrupt the Foxp3-NFAT interaction impair the ability of Foxp3 to repress Il2, activate Ctla4 and Cd25, and confer suppressive activity when expressed in normal T cells. Although four known types of NFAT may function redundantly, mice deficient in both NFATc2 and NFATc3 spontaneously develop severe lymphoadenopathy and selective activation of Th2 cells accompanying hyperproduction of IgE, suggesting that the deficiency might disrupt the function of Foxp3 and consequently impair Treg function (Ranger et al., 1998). AML1/Runx1 is crucial for normal hematopoiesis including thymic T cell development (Taniuchi et al., 2002) . It is expressed in conventional T cells and to a slightly lesser degree in natural Tregs (Ono et al., 2007) . In contrast with NFAT, which is dephosphorylated by calcineulin and translocates from the cytoplasm to the nucleus upon T cell activation, AML1/Runx1 may constitutively bind to the Il2 promoter at the site upstream to the binding sites of NFAT, AP-1, and NF-kB. Upon T cell activation, it may act as an organizing factor that facilitates the assembly of transcriptional activation complexes containing NFAT on the Il2 promoter. Alternatively, AML1/Runx1, alone or together with its interacting partners such as p300 and CREB-binding protein, may cooperate with the NFAT transcription complex to activate the Il2 promoter. In contrast, in Tregs, AML1/Runx1 physically binds to Foxp3 at its N-terminal region between the leucine zipper domain and the forkhead box ( Figure 3A ). Disrupting the binding between Foxp3 and AML1/Runx1 impairs the Foxp3-dependent suppression of IL-2 production and attenuates suppressive activity without affecting the binding of Foxp3 to NFAT. Knockdown of AML1/Runx1 in natural Tregs abrogates their suppressive activity. Further, Tregspecific disruption of the AML1/Runx1 gene in mice affects Foxp3 function and causes autoimmune disease similar to that produced by Treg depletion (A. Kitoh, M.O., and S.S., unpublished data).
Transcriptional control exerted by Foxp3 also involves HATs, such as TIP60, and HDACs, such as HDAC7 and HDAC9 (Li and Greene, 2007) (Figure 3A ). Acetylation of Foxp3 by TIP60 enhances the binding of Foxp3 to the Il2 promoter and augments the repression of Il2 (Chen et al., 2006) . It remains to be determined how the interaction of Foxp3 with coactivators and corepressors modifies the function of NFAT and AML1/ Runx1 and controls the expression of Foxp3 target genes including Il2, Cd25, Ctla4, and Gitr.
Another approach to understanding how Foxp3 controls Treg function is to identify Foxp3 target genes genomewide. Transcriptome analysis has revealed several genes, such as those encoding G protein-coupled receptor 83 (Gpr83) or Extracellular matrix 1 (Ecm1), that are predominantly expressed in natural Tregs and Foxp3-transduced T cells.
Other genes, such as those encoding Granzyme B and the transcription factor Helios, are highly specific to Tregs but are apparently expressed independently of Foxp3 (Fontenot et al., 2005; Sugimoto et al., 2006; Hill et al., 2007) . Retroviral transduction of either group of genes in CD25 − CD4 + T cells failed to confer suppressive activity in vitro (Sugimoto et al., 2006) . Recent searches for Foxp3 target genes have shown that Foxp3 directly or indirectly controls hundreds (~700) of genes and binds directly to ~10% of them (Marson et al., 2007; Zheng et al., 2007) . Foxp3-binding genes include those encoding signal transduction molecules (such as Zap70 and Ptpn22), transcription factors (such as Crem), cytokines (e.g., Il2), cell-surface molecules (such as Il2ra, Ctla4, and FasL), enzymes for cell metabolism (such as Pde3b), and intergenic microRNAs (such as miR-155). microRNAs do indeed appear to play an important role in Treg development. T cell-specific Taken together, the characterization of Foxp3 interacting partners and Foxp3 target genes has revealed that Foxp3 interacts with transcription factors (such as NFAT and AML1/ Runx1) that otherwise facilitate the activation of non-Treg cells and their differentiation into effector T cells. This suggests a model of Foxp3 function, in which Foxp3 overrides or hijacks the transcription machinery for effector T cells, thereby functionally converting them to Tregs ( Figure 3B ). Supporting this model, in mice genetically engineered to express a substantially lower amount of Foxp3 than normal, natural Tregs not only lose suppressive activity but also spontaneously differentiate to effector T cells that secrete IL-2, IFN-γ, and IL-4 (Wan and Flavell, 2007) . Furthermore, Foxp3 may interact with RORγt, a key transcription factor for the differentiation of naive T cells to Th17 cells, and thereby inhibit Th17 differentiation (Bettelli et al., 2006 , and see below). It remains an open question as to how the Foxp3 complex containing NFAT and AML1/ Runx1 (together with HATs and HDACs) controls the genes that mediate suppression. In addition, the existence of genes that are highly Treg specific but Foxp3 independent suggests that there might be a higher level of transcriptional regulation upstream of Foxp3 or coregulation of Treg differentiation and function with other transcription factors.
The Antigen Recognition Repertoire of Tregs A cardinal feature of Foxp3 + natural Tregs is that unlike the majority of thymus-produced naive T cells, they are already functionally mature (that is, competent to prevent autoimmune disease and exert suppression in vitro) and "antigenprimed" in the thymus, before encountering antigen in the periphery (Sakaguchi et al., 1982; Itoh et al., 1999 (Jordan et al., 2001; Kawahata et al., 2002) . In contrast, Tregs fail to develop when double-transgenic mice express either a low-affinity transgenic TCR or a high concentration of the peptide, presumably due to insufficient positive selection or strong negative selection, respectively. This apparently high self-reactivity of Foxp3 + cells could be a consequence of positive selection of highly self-reactive T cells to the Treg lineage or a resistance of differentiated Foxp3 + cells to negative selection (van Santen et al., 2004) . Second, in TCR transgenic mice, which spontaneously develop CD25 + CD4 + Tregs in an equivalent number as in nontransgenic mice, Tregs predominantly express endogenous TCR α chains paired with the transgenic β chain. In contrast, the majority of CD25 − CD4 + T cells express the TCR solely composed of transgenic α and β chains (Itoh et al., 1999) . RAG deficiency, which blocks gene arrangement at the endogenous TCR α chain locus, abrogates the development of CD25 + CD4 + Tregs in TCR transgenic mice, indicating that self-reactive TCRs utilizing endogenous α chains may contribute to the positive selection of thymocytes to Tregs. The lack of Tregs due to RAG deficiency exacerbates autoimmune disease in mice expressing autoimmune transgenic TCRs. Third, a mutation in the gene encoding LAT (linker of activated T cell), a TCR proximal signal transduction molecule, abolishes the generation of Foxp3 + Tregs in the thymus and periphery while allowing the development of other T cells. This indicates that Treg development requires a strong signal via the TCR in the thymus (Koonpaew et al., 2006) . Furthermore, in TCRβ-fixed transgenic mice with a single copy of the TCRα locus or a "mini-TCRα" transgenic locus (which inhibits the appearance of T cells expressing double α chains), sequence analyses of TCR Vα segments of a particular Vα subfamily in CD25 + or CD25 − CD4 + T cells have revealed distinct repertoires of the two populations, although the degree of overlap needs to be assessed more precisely (Hsieh et al., 2006; Pacholczyk et al., 2007) .
In addition to the affinity of the interaction between the TCR and self-peptide/MHC, the intensity of the interaction between T cell accessory molecules and their ligands on thymic stromal cells contributes to the generation of natural Tregs. For example, deficiency of CD28, CD40, CD11a/ CD18 (LFA1), or CD80 and CD86 (B7) results in a substantial reduction of CD25 + CD4 + Tregs in the thymus and periphery (reviewed in Sakaguchi, 2005) .
At the cellular level, both medullary thymic epithelial cells (mTECs) and dendritic cells in the thymus contribute to Treg generation as well as negative selection of naive T cells. Deficiency in the tumor necrosis factor receptor-associated factor 6 (TRAF6) or NF-κB-inducing kinase results in the absence of mature mTECs, hampering the development of Tregs (Akiyama et al., 2005; Kajiura et al., 2004) . In humans, the cytokine TSLP (thymic stromal lymphopoietin) secreted by Hassal's corpuscles, which are derived from mTECs, appears to act on thymic dendritic cells to promote the differentiation of thymocytes to Tregs (Watanabe et al., 2005) . A population of mTECs ectopically express a set of tissue-specific antigens (TSAs), such as insulin, under direct or indirect control of the gene Aire (autoimmune regulator) (reviewed in Mathis and Benoist, 2007) . Interestingly, Aire-deficient mice spontaneously develop autoimmune diseases similar to those produced by Treg depletion. A recent study has suggested that Aire + mTECs expressing TSAs may induce or facilitate the development of TSA-specific Tregs in normal thymus, and that a paucity of TSA-specific Tregs may contribute to the occurrence of autoimmune disease in Aire deficiency (Aschenbrenner et al., 2007) .
Thus, the avidity of interaction between thymocytes and stromal cells is critical in determining the fate of developing thymocytes to the Treg lineage. Interestingly, recent studies suggest that Foxp3 per se is not required for this initial cell fate determination in the thymus Gavin et al., 2007) . In mice in which the Foxp3 encoding region is replaced by a green fluorescent protein (GFP) reporter, GFPpositive thymocytes, which do not express the Foxp3 protein, exhibit some elements of the Treg phenotype (including the expression of Treg-associated cell-surface molecules, such as CD25), although they are not suppressive in vitro. This indicates that the interaction of developing thymocytes with thymic stromal cells turns on a program of transcriptional regulation in parallel with or upstream of Foxp3, and that once the Foxp3 gene is switched on, Foxp3 may stabilize and sustain the Treg phenotype and confer suppressive activity. Future efforts will examine how spatiotemporal interactions between thymocytes and stromal cells turn on the Treg differentiation program in developing thymocytes. Specifically, it needs to be determined whether the intensity of signaling via the TCR and accessory molecules alone is sufficient for cell fate determination to the Treg lineage or whether stromal cell-derived humoral factor(s) including cytokines are also required. It is also unclear how the interaction evokes Foxp3 expression in Treg-committed thymocytes ( Figure 4B ).
Peripheral Generation of Tregs from Naive T Cells Naive T cells in the periphery can also acquire Foxp3 expression and consequently Treg function in several experimental settings, for example, in vitro antigenic stimulation of naive T cells in the presence of TGF-β (Chen et al., 2003; Apostolou and von Boehmer, 2004; Kretschmer et al., 2005) . In TGF-β-dependent in vitro Treg induction, IL-6 hampers the differentiation of naive T cells to Foxp3 + cells (Bettelli et al., 
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2006). Interestingly, TGF-β stimulation in the presence of IL-6 facilitates T cell differentiation to Th17 cells in mice (Veldhoen et al., 2006; Bettelli et al., 2006) . IL-2 facilitates the differentiation of naive CD4 + T cells into Foxp3 + Tregs but inhibits their differentiation into Th17 cells . Additionally, retinoic acid, which is secreted by a particular subset of dendritic cells in the gut-associated lymphoid tissue, inhibits IL-6-driven induction of Th17 cells. In the presence of TGF-β, retinoic acid facilitates the differentiation of naive T cells to Foxp3 + Tregs (Benson et al., 2007; Mucida et al., 2007; Sun et al., 2007; Coombes et al., 2007) . Hence, orally administered protein antigens presented by retinoic acid-producing dendritic cells in the gut-associated lymphoid tissue may induce Foxp3 + Tregs. This could be a plausible mechanism of oral tolerance ( Figure 5 ).
Yet, it remains to be determined whether Tregs induced from naive T cells in the periphery are functionally stable in vivo and to what extent they contribute to the peripheral pool of Foxp3 + Tregs ( Figure 4A ). For example, in mice the regulatory regions of the Foxp3 gene are more widely demethylated in natural Tregs than in TGF-β-induced Tregs, suggesting functional instability of the latter (Floess et al., 2007) . In addition, unlike mice, naive T cells in humans readily express Foxp3 upon TCR stimulation, although the expression is generally much lower and more transient than in natural Tregs (Yagi et al., 2004; Gavin et al., 2006) . Assuming that Foxp3 can suppress possible effector programs in T cells, it is an intriguing question whether Foxp3 not only confers suppressive function to natural Tregs but also may serve as an intrinsic brake to the further activation of antigen-stimulated effector T cells in humans.
Besides Foxp3 + Tregs, there are other types of Treg cells that can be induced from naive T cells in the periphery; for instance, CD4 + T cells secreting IL-10 and TGF-β, called Tr1 cells, are produced in vitro by antigenic stimulation of naive T cells in the presence of IL-10 (Chen et al., 1994; Groux et al., 1997) . Antigen-specific TGF-β-secreting T cells, called Th3 cells, were originally propagated from animals that became tolerant to orally administered protein antigen. At least some Th3 cells appear to be TGF-β-induced Foxp3 + Tregs. Tr1 cells do not express Foxp3, yet their properties in vitro are very similar to those of Foxp3 + Tregs. For example, they exhibit diminished proliferation in response to antigenic stimulation, exert cell contact-dependent suppression, scarcely produce IL-2, and display an activated cell-surface phenotype (Vieira et al., 2004) . It is likely that Tr1 and natural Foxp3 + Tregs may share some common suppressive mechanims in vitro, although long-term stability of Tr1 and Th3 cells needs to be further assessed in vivo.
A variety of other T cell subpopulations including CD8 + , CD4 − CD8 − , and γ/δ T cells have also been reported to exhibit an immunosuppressive activity (reviewed in Shevach, 2006) . There is so far little evidence that they play crucial roles in natural self-tolerance. CD8 + suppressor T cells were widely and intensively studied in the 1970s but have defied precise molecular characterization. These cells may now need to be recharacterized with currently available molecular tools. It is noteworthy that antigen immunization with strong adjuvant expands not only CD4 + Foxp3 + T cells but also CD8 + Foxp3 + T cells from a number that is negligible in unimmunized mice . These cells could plausibly correspond to some of the antigen-induced CD8 + suppressor T cells previously described (Cantor et al., 1976) .
Trafficking and Localization of Tregs
Where are Foxp3 + natural Tregs found in the body? Dendritic cells in the draining lymph nodes present tissue-specific selfantigens (Scheinecker et al., 2002) , and Foxp3 + Tregs specific for tissue self-antigens are enriched in the regional lymph nodes (Samy et al., 2005) . This indicates that antigen-specific Tregs migrate to and become activated in regional lymph nodes where tissue-specific self-antigens or microbial antigens are presented. They also migrate into inflamed tissues, infectious sites, and tumors (Belkaid et al., 2002) . In addition to TCRs that recognize specific antigens, Foxp3 + Tregs express a spectrum of homing receptors, including adhesion molecules and chemokine receptors (Huehn and Hamann, 2005) . In the peripheral lymph nodes, the majority (~80%) of Foxp3 + Tregs express CCR7 at high levels. Foxp3 + Tregs are slightly higher than Foxp3 − T cells in the expression of CCR4, CCR6, CXCR4, and CXCR5. A fraction (~30%) of Foxp3 + Tregs express CD103 (integrin α E β 7 ), which interacts with its ligand E-cadherin expressed by epithelial cells; a substantial fraction (~50%) highly express CD62L (L-selection), which interacts with the vascular addressins CD34, GlyCAM-1, and MAdCAM-1 expressed by the endothelium in lymph nodes and mucosal lymphoid tissue (reviewed in Huehn and Hamann, 2005) . The expression of these homing receptors The expression patterns of homing receptors correlate with the functional heterogeneity of Tregs. CCR7 + CD62L high Tregs, which migrate to the secondary lymphoid tissues, have an enhanced capacity to prevent the development of autoimmune diabetes in a mouse model, suggesting suppression of self-reactive T cells in the regional lymph nodes (Szanya et al., 2002 (Yurchenko et al., 2006) .
The expression patterns of homing receptors are basically similar to those of effector T cells migrating to the same tissue site. CCR4 + Tregs as well as CCR4 + effector T cells accumulate in inflamed skin following local antigen inoculation (Sather et al., 2007) . CCR6 + Tregs and CCR6 + Th17 cells are both elevated in inflamed joints in an animal model of rheumatoid arthritis . Additionally, retinoic acid secreted by intestinal CD103 + dendritic cells induces guthoming integrin α 4 β 7 in Tregs and non-Treg cells.
Treg-specific deficiency of a particular homing receptor or its blockade compromises Treg function, for example, in the control of tissue-localized inflammation, local maintenance of allograft tolerance, and fetomaternal tolerance Yurchenko et al., 2006; Schneider et al., 2007; Sather et al., 2007; Kallikourdis et al., 2007) . Thus, migration receptors on Tregs are highly informative in assessing Treg behavior in vivo and can be exploited to control immune responses through altering Treg trafficking and localization.
Treg Activation, Proliferation, and Differentiation Upon antigen exposure in the regional lymph nodes, Foxp3 + Tregs become activated and exert suppression at a much lower concentration of antigen than naive T cells. In TCR transgenic mice, the concentration of peptide required to activate the peptide-specific Tregs to exert suppression in vitro has been estimated to be 10-to 100-fold lower than the concentration needed for activating naive T cells with the same antigen specificity (Takahashi et al., 1998) . This finding suggests that natural Tregs can be activated even by immature dendritic cells whose expression levels of CD80/86 and self-peptide/MHC are too low to activate naive self-reactive T cells. This might enable natural Tregs to exert dominant and tonic suppression of self-reactive T cells. It could also contribute to the prevention of autoimmunity stemming from molecular mimicry (the antigenic crossreaction between a self-molecule and a microbial substance) because natural Tregs could be more easily activated than self-reactive T cells by such a substance (Stephens et al., 2005) .
Notably, unlike their hypoproliferation upon antigenic stimulation in vitro, a sizable fraction of Foxp3 + natural Tregs are continuously proliferating in vivo presumably through the recognition of selfantigen and commensal microbes (Fisson et al., 2003; Setoguchi et al., 2005) . Natural Tregs can also expand clonally in vivo and in vitro following antigenic stimulation and retain their suppressive function after expansion (Klein et al., 2003; Yamazaki et al., 2003; Fehérvári and Sakaguchi, 2004; Yamaguchi et al., 2007) .
Various stimuli via accessory molecules expressed by Foxp3 + Tregs also lead to their expansion in vivo and in vitro. Stimulation of GITR, which is constitutively expressed in Tregs at a higher level than in other T cells, facilitates vigorous proliferation of Tregs in the presence of IL-2 in vitro (McHugh et al., 2002; Shimizu et al., 2002) . In addition, Tregs can expand following stimulation via Toll-like receptors (TLRs), independent of TCR recognition of a specific antigen. Tregs respond to ligands for TLR2, 4, 5, and 8, including bacterial flagellin that acts through TLR5 (reviewed in Sutmuller et al., 2006) . A similar effect is observed with 60 kDa heat shock protein, a self-molecule, with Pam3Cys via mouse TLR2, or with lipopolysaccharide via TLR4.
Irrespective of active proliferation the number of Foxp3 + natural Tregs is fairly constant in normal animals (10%-15% of CD4 + T cells), indicating that cell death helps to maintain Treg homeostasis. Indeed, following antigenic stimulation Tregs downregulate Bcl-2, an antiapoptotic protein Alternatively, absorption of cytokines by Tregs may induce apoptosis in responder T cells (Pandiyan et al., 2007) . Tregs might also kill responder T cells or APC through cell-to-cell contact by a granzyme-or perforin-dependent mechanism, or through delivery of a negative signal to responder T cells. Possible negative signals include upregulation of intracellular cyclic AMP, which leads to inhibition of T cell proliferation and IL-2 production, or the generation of pericellular adenosine catalyzed by CD39 (ectonucleoside triphosphate diphosphohydrolase 1) and CD73 (ecto-5′-nucleotidase) expressed by Tregs (reviewed in Tang and Bluestone, 2008) . Activated Tregs may also downmodulate CD80/86 expression on APC or stimulate dendritic cells to form the enzyme indoleamine 2, 3-dioxygenase, which catabolizes the essential amino acid tryptophan to kynurenines that are toxic to T cells; both appear to be dependent on the expression of CTLA-4 by Tregs.
Taken together, these findings suggest a model of Tregmediated suppression: (1) upon antigenic stimulation, antigen-specific Tregs, which are highly mobile, are swiftly recruited via chemokines to dendritic cells presenting the antigen and out-compete antigen-specific naive T cells in aggregating around the dendritic cells; (2) antigen-activated Tregs contacting dendritic cells then downmodulate dendritic cell function, thereby hindering the activation of other T cells that are recruited to the dendritic cells; (3) Tregs may then further differentiate to secrete granzyme/perforin, IL-10, or other immunosupressive cytokines (such as IL-35) depending on the strength and duration of antigenic stimulation and the local milieu of cytokines and other substances (Figure 6 ). Consistent with this model, intravital imaging of Tregs and responder T cells in a lymph node by two-photon microscopy suggests that activated Tregs hamper stable contacts between responder T cells and antigen-presenting dendritic cells (Tang et al., 2006; Tadokoro et al., 2006) . Assuming that in vivo activation of a naive T cell is a process that requires contact with an antigen-presenting dendritic cell for several hours (Celli et al., 2007) , Treg-mediated interference may suffice to render abortive the activation of responder T cells, thereby suppressing an immune response.
Deficiencies of some Treg-expressing molecules (such as LAG3, granzymes, and IL-35) can impair Treg suppression in vitro by affecting a particular mode of suppression but fail to cause autoimmunity in vivo because other modes may effectively compensate for the deficiencies. Among the various molecules involved in suppression in vivo or in vitro, CTLA-4 is critically important for the following reasons. Foxp3 + Tregs constitutively express CTLA-4, Foxp3 directly controls the expression of CTLA-4, and CTLA-4 blockade abrogates suppression. Further, not only germline deletion but also Treg-specific conditional deficiency of CTLA-4 induces fatal autoimmunity/inflammation in mice (Salomon et al., 2000; Read et al., 2000; Takahashi et al., 2000 ; K. Wing and S.S., unpublished data). Additional study is required to elucidate the molecular basis of suppression mediated by Tregs. The fate of responder T cells that are suppressed by Tregs is also unclear, that is, whether they remain nonactivated, die by apoptosis, or become anergic.
Tregs: A Clinical Perspective
To what extent are Treg anomalies responsible for immunological diseases in humans and how might Tregs be exploited to control physiological and pathological immune responses?
Polymorphisms of several genes including Ctla4, Il2, Cd25, and Ptpn22 significantly contribute to genetic susceptibility to common autoimmune diseases, such as type I diabetes (Wellcome Trust Case Control Consortium, 2007) . Deficiency of these genes, in particular Ctla4, Il2, and Cd25, produces severe autoimmunity in mice presumably through an effect on Treg development and function. Similarly, CTLA-4 blockade or IL-2 neutralization for a limited period elicits T cellmediated autoimmune disease in otherwise normal mice. It is therefore possible that the polymorphisms of these genes may alter Treg development or function and thereby render the host susceptible to autoimmune disease (Yamanouchi et al., 2007) . Environmental factors might also affect Tregs and thereby contribute to the development of autoimmunity. Tregs display greater proliferation and higher metabolic activity than non-Tregs under physiological conditions. As a consequence, they are more sensitive to ionizing radiation, radiomimetic drugs (such as cyclophosphamide), and deficiency of certain vitamins such as folic acid (Fisson et al., 2003; Brode et al., 2006; Setoguchi et al., 2005; Yamaguchi et al., 2007) .
Although Treg depletion can evoke autoimmunity, it can also provoke and enhance tumor immunity in rodents (Shimizu et al., 1999) (Figure 1) . In vitro T cell responses against tumor-associated antigens are enhanced by stimulating T cells from cancer patients (or even normal individuals) with tumor antigen after the depletion of natural Tregs (Danke et al., 2004; Nishikawa et al., 2005) . In addition, Foxp3 + Tregs are abundant in tumors. Thus, natural Tregs that promote self-tolerance may act to impede immune surveillance against cancers in normal individuals and suppress potential responsiveness to autologous tumors in cancer patients. Targeting Tregs is a promising approach for cancer immunotherapy. Such approaches could include local depletion of Tregs in the tumor mass, attenuation of Treg function at the time of therapeutic vaccination with tumor antigen, and ex vivo expansion of tumor-infiltrating lymphocytes after the depletion of Tregs.
Similar to tumor immunity, depletion or reduction of natural Tregs enhances immune responses to pathogenic microbes (reviewed by Belkaid and Rouse, 2005 ). Yet, complete eradication of microbes via Treg depletion might hamper the development of effective immunological memory for the microbes, thus impairing the secondary immune responses upon reinfection (Belkaid et al., 2002) . Hence, Tregs control the quality and tune the magnitude of antimicrobial immune responses to protect the host from pathogenic microbes while avoiding collateral immunopathology or inappropriate responses to commensal microbes. Foxp3 + natural Tregs retain their suppressive function after expansion in vivo and in vitro. By exploiting this stable suppressive activity and proliferative capacity, strategies that clonally expand antigen-specific natural Tregs while inhibiting the activation and expansion of effector T cells will help to induce transplantation tolerance and suppress graft rejection. Furthermore, in the presence of Tregs that actively maintain graft tolerance, naive T cells could be newly recruited to the graft site and could differentiate into graftspecific Tregs, thereby augmenting graft tolerance (Waldmann et al., 2006) . The same principle could be applied to the treatment of autoimmune disease, as well as allergy, and inflammatory diseases and might be used to augment fetomaternal tolerance in pregnancy.
For the purpose of attenuating or enhancing Treg-mediated immune suppression in various clinical settings, it is necessary to find a specific molecular marker that can selectively and reliably differentiate between Tregs and effector T cells. Biologicals, such as monoclonal antibodies, and small molecules that have differential effects on Tregs and effector T cells may represent the next generation of therapeutic reagents to selectively suppress or enhance immune responses by controlling the balance between Tregs and effector T cells. Further elucidation of the cellular and molecular processes underlying the development and function of Tregs will help to establish new strategies for the treatment and prevention of immunological diseases and for the control of a wide spectrum of physiological immune responses.
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